SAN DIEGO, April 27 /PRNewswire-FirstCall/ -- Nanogen, Inc.
(Nasdaq: NGEN), developer of advanced diagnostic products, announced today
that it has been issued European Patent No. 0943158B1, "Affinity Based
Self-Assembly Systems and Devices for Photonic and Electronic Applications,"
by the European Patent Office. This patent is similar to U.S. Patent
6,652,808, the parent of a series of patent applications that significantly
broaden Nanogen's proprietary position in the nanotechnology and
nanomanufacturing areas. The U.S. patent was issued in December 2003.
The new nanotechnology patent relates to a nanofabrication technology that
combines an electric field assisted manufacturing platform and programmable
self-assembling nanostructures (for example, DNA building blocks) for the
fabrication of a wide range of unique higher-order nano and microscale
devices, structures and materials. The nanofabrication platform and process
would be used for: producing nanoscale electronic and photonic devices and
structures; assembly of nanostructures and submicron components onto silicon
wafers and other materials; integration of nanostructures within preformed
microelectronic and optoelectronic structures; production of nanoparticles
(for example, photonic crystals, nanospheres and quantum dots); and
fabrication of selectively addressable DNA nanoarray substrates and materials.
The patent represents a unique nanofabrication technology that combines
the best aspects of top-down microfabrication processes with bottom-up
biological self-assembly processes for producing novel nanodevices and
nanostructures. The European patent is jointly owned by Nanotronics, Inc., a
wholly owned subsidiary of Nanogen, and the Regents of the University of
California. Nanogen has exclusively licensed the interests of the University
of California where there is joint inventorship.
About Nanogen, Inc.
Nanogen's advanced diagnostics provide physicians and patients worldwide
with sophisticated information to predict, diagnose and treat disease.
Research and clinical reference labs use the highly accurate and reliable
NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarray
and broad suite of analyte specific reagents to develop diagnostic tests for
variety of diseases. Nanogen also offers a broad portfolio of patented
nucleic acids chemistries and molecular tools that accelerate genomic analysis
and are compatible with many systems. The SynX subsidiary offers a line of
point-of-care diagnostic tests and is building expertise in cardiac related
health conditions. Nanogen's ten years of pioneering research involving
nanotechnology may also have future applications in medical diagnostics,
biowarfare and other industries. For additional information please visit
Nanogen's website at www.nanogen.com.
Nanogen Forward-Looking Statement
This press release contains forward-looking statements that are subject to
risks and uncertainties that could cause actual results to differ materially
from those set forth in the forward-looking statements, including whether
patents owned or licensed by Nanogen will be developed into products, whether
the patents owned by Nanogen offer any protection against competitors with
competing technologies, whether products under development can be successfully
developed and commercialized, whether results reported by our customers or
partners can be identically replicated, and other risks and uncertainties
discussed under the caption "Factors That May Affect Results" and elsewhere in
Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date hereof. Nanogen disclaims any intent or obligation to update these
SOURCE Nanogen, Inc.